journal article·2017-06-14

Nanoengineered Stent Surface to Reduce In-Stent Restenosis in Vivo

Harald Nuhn, Cesar E. Blanco, Tejal A. Desai

Publisher page

Abstract

In-stent restenosis (ISR) is the leading cause of stent failure and is a direct result of a dysfunctional vascular endothelium and subsequent overgrowth of vascular smooth muscle tissue. TiO 2 nanotubular (NT) arrays have been shown to affect vascular endothelial cells (VECs) and vascular smooth muscle cells (VSMCs) in vitro by accelerating VEC cell proliferation and migration while suppressing VSMCs. This study investigates for the first time the potentially beneficial effects of TiO 2 NT arrays on vascular tissue in vivo . TiO 2 NT arrays (NT diameter: 90 ± 5 nm, height: 1800 ± 300 nm) were grown on the surface of titanium stents and characterized in terms of surface morphology and stability. Stents were implanted into the iliofemoral artery using an overinflation model (rabbit). After 28 days, stenosis rates were determined. The data show a statistically significant reduction of stenosis by 30% compared to the control. Tissue in the presence of TiO 2 NTs appears more mature, and less neointima is present between struts. In addition, the extra cellular matrix secreted by cells at the interface of the NT arrays shows complete integration into the nanostructured surface. These results document the accelerated restoration of a functional endothelium in the presence of TiO 2 NT arrays and substantiate their beneficial impact on vascular tissue in vivo . Our findings suggest that TiO 2 NT arrays can be used as a drug-free approach for keeping stents patent long-term and have the potential to address ISR.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Coronary Interventions and Diagnostics · Aortic aneurysm repair treatments · Intracranial Aneurysms: Treatment and Complications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California, 1042 Downey Way, DRB Building, Suite 101, Los Angeles, California 90089-1112, United States

Department of Bioengineering and Therapeutic Sciences and The UC Berkeley−UCSF Graduate Group in Bioengineering, University of California—San Francisco, San Francisco, California 94158, United States

Funding

National Institutes of Health · Alfred E. Mann Institute for Biomedical Engineering, University of Southern California

References (42)

Show source-provided references
1. 10.1016/j.jacc.2014.02.54510.1016/j.jacc.2014.02.545 ↗
2. 10.1038/nrcardio.2012.6410.1038/nrcardio.2012.64 ↗
3. 10.1161/01.ATV.0000037100.44766.5B10.1161/01.ATV.0000037100.44766.5B ↗
4. 10.1161/01.CIR.0000163587.36485.A710.1161/01.CIR.0000163587.36485.A7 ↗
5. 10.1161/01.CIR.77.2.36110.1161/01.CIR.77.2.361 ↗
6. 10.1016/j.jacc.2007.06.05610.1016/j.jacc.2007.06.056 ↗
7. 10.1016/S0140-6736(04)17275-910.1016/S0140-6736(04)17275-9 ↗
8. 10.1161/ATVBAHA.107.14422010.1161/ATVBAHA.107.144220 ↗
9. 10.1161/CIRCULATIONAHA.107.69373910.1161/CIRCULATIONAHA.107.693739 ↗
10. 10.1177/030098581140044610.1177/0300985811400446 ↗
11. Holmes D. R. · 2009 · 95
12. 10.1002/1522-726X(200007)50:3<290::AID-CCD5>3.0.CO;2-W10.1002/1522-726X(200007)50:3<290::AID-CCD5>3.0.CO;2-W ↗
13. 10.1161/01.CIR.103.23.281610.1161/01.CIR.103.23.2816 ↗
14. 10.1016/S0735-1097(03)00119-010.1016/S0735-1097(03)00119-0 ↗
15. 10.1016/j.amjcard.2003.10.04910.1016/j.amjcard.2003.10.049 ↗
16. 10.1021/nl501523v10.1021/nl501523v ↗
17. 10.1021/nl903043z10.1021/nl903043z ↗
18. 10.1016/j.biomaterials.2008.11.01210.1016/j.biomaterials.2008.11.012 ↗
19. 10.1021/nl900105210.1021/nl9001052 ↗
20. 10.1371/journal.pone.015572610.1371/journal.pone.0155726 ↗
21. 10.1021/nl072572o10.1021/nl072572o ↗
22. 10.1002/jbm.a.3564610.1002/jbm.a.35646 ↗
23. 10.1002/anie.20100137410.1002/anie.201001374 ↗
24. 10.1002/cphc.20030101410.1002/cphc.200301014 ↗
25. 10.1039/B815634D10.1039/B815634D ↗
26. 10.1021/nl070678d10.1021/nl070678d ↗
27. 10.1073/pnas.081320010610.1073/pnas.0813200106 ↗
28. 10.1021/acsbiomaterials.5b0055310.1021/acsbiomaterials.5b00553 ↗
29. 10.1002/jbm.a.3226210.1002/jbm.a.32262 ↗
30. 10.4236/jbnb.2011.2303610.4236/jbnb.2011.23036 ↗
31. 10.1016/0002-8703(94)90505-310.1016/0002-8703(94)90505-3 ↗
32. 10.1016/S1054-8807(98)00019-210.1016/S1054-8807(98)00019-2 ↗
33. 10.1016/j.jvs.2009.10.08010.1016/j.jvs.2009.10.080 ↗
34. 10.1161/01.ATV.9.3.28910.1161/01.ATV.9.3.289 ↗
35. Hampshire, V.Guidance for Industry and FDA Staff: General Considerations for Animal Studies for Cardiovascular Devices.Food and Drug Administration Center for Devices and Radiological Health, July 2010.
36. 10.1161/01.CIR.0000033485.20594.6F10.1161/01.CIR.0000033485.20594.6F ↗
37. 10.1016/j.electacta.2009.05.06410.1016/j.electacta.2009.05.064 ↗
38. 10.1016/S0008-6363(97)00326-X10.1016/S0008-6363(97)00326-X ↗
39. 10.1161/01.CIR.82.6.219010.1161/01.CIR.82.6.2190 ↗
40. 10.1208/s12248-010-9175-310.1208/s12248-010-9175-3 ↗
41. 10.1016/j.actbio.2009.05.00810.1016/j.actbio.2009.05.008 ↗
42. 10.1161/01.CIR.0000019071.72887.BD10.1161/01.CIR.0000019071.72887.BD ↗